IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines

Soininen, Anu; Seppälä, Ilkka; Nieminen, Tea; Eskola, Juhani; Käyhty, Helena

doi:10.1016/s0264-410x(98)00475-7

Cited by 67 publications

(58 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using the adult serum panel, the geometric mean IgG1/ IgG2 ratios were well less than 1 for serotypes 9V and serotype 14, 0.07 and 0.04, respectively. This predominance of IgG2 antibodies in adult sera postvaccination is consistent with results from prior postvaccination studies where the IgG subclass levels against serotype 14 and other serotypes were assessed (30,41). In contrast, the geometric mean ratios for the pediatric serum panel of postimmunization sera showed a predominance of IgG1 (i.e., ratios greater than 1) for serotypes 9V and 14, 2.35 and 1.45, respectively.…”

Section: Resultssupporting

confidence: 86%

“…Furthermore, because of differences in immune status and in natural exposure to S. pneumoniae and cross-reactive antigens, the subclass response of adults and children to pneumococcal conjugate vaccines may differ (2,41). To assess this, the ratios of IgG1 to IgG2 in the panels of adult and pediatric sera were examined in both the serotype 9V-and 14-specific EIAs (Table 3).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Assignment of Weight-Based Immunoglobulin G1 (IgG1) and IgG2 Units in Antipneumococcal Reference Serum Lot 89-S(F) for Pneumococcal Polysaccharide Serotypes 1, 4, 5, 7F, 9V, and 18C

Sikkema

Jones

et al. 2005

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

Section: Resultssupporting

confidence: 86%

Section: Resultsmentioning

confidence: 99%

Assignment of Weight-Based Immunoglobulin G1 (IgG1) and IgG2 Units in Antipneumococcal Reference Serum Lot 89-S(F) for Pneumococcal Polysaccharide Serotypes 1, 4, 5, 7F, 9V, and 18C

Sikkema

Jones

et al. 2005

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…32,33 Antibodies to pneumococcal capsular polysaccharides are mainly of the IgG1 subclass in young children, 34 but the Pnc PS vaccine induces predominantly IgG2 subclass antibody production in adults. 35,36 The IgG2 response to the Pnc PS vaccine in paediatric BMT recipients has been impaired compared to that of healthy age-matched controls. 37 In previous studies including both adult and paediatric BMT recipients, the Hib conjugate vaccine has induced predominantly IgG1 subclass Hib antibodies and plain Hib PS and Pnc PS vaccines have alternatively induced predominantly IgG1 or IgG2 subclass antibodies.…”

Section: Discussionmentioning

confidence: 99%

IgG subclasses and avidity of antibodies to polysaccharide antigens in allogeneic BMT recipients after vaccination with pneumococcal polysaccharide and Haemophilus influenzae type b conjugate vaccines

Parkkali

Käyhty

Anttila

et al. 1999

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is well established that some bacterial CPSs, when used as vaccines, are capable of eliciting protective antibodies via T-cell-independent mechanisms. When the IgG response to bacterial capsules is present, IgG2 usually predominates (33), and these antibodies are relatively poor opsonins that weakly activate the complement cascade. To enhance the host antibody response and to switch the IgG subtype response to these antigens, CPSs have been conjugated to carrier molecules (1,14).…”

Section: Vol 71 2003 Notes 2285mentioning

confidence: 99%

Immunization withPorphyromonas gingivalisCapsular Polysaccharide PreventsP. gingivalis-Elicited Oral Bone Loss in a Murine Model

González¹,

Tzianabos

Genco

et al. 2003

Infect Immun

View full text Add to dashboard Cite

The capsular polysaccharide (CPS) of the periodontal pathogen Porphyromonas gingivalis is an important virulence factor for this organism. We purified P. gingivalis CPS, immunized mice with this antigen, and assessed the vaccine potential of P. gingivalis CPS by using the murine oral challenge model. Animals immunized with P. gingivalis CPS developed elevated levels of immunoglobulin M (IgM) and IgG in serum that reacted with whole P. gingivalis organisms. The mice immunized with P. gingivalis CPS were protected from P. gingivalis-elicited oral bone loss. These data demonstrate that P. gingivalis CPS is a vaccine candidate for prevention of P. gingivalis-elicited oral bone loss.Porphyromonas gingivalis has emerged as a leading pathogen implicated in generalized, aggressive periodontal disease, a chronic inflammatory disease of the supporting tissues of the teeth (16,17,23). The mechanism by which this gram-negative encapsulated anaerobe initiates periodontal disease is not fully known; however, bacterial and host factors are both critical to this process (12,15). P. gingivalis possesses a broad array of virulence factors that allow this organism to cause disease, including fimbriae, gingipains, hemagglutinins, lipopolysaccharide (LPS), and others, such as capsular polysaccharide (CPS) (15). Using a murine model, van Winkelhoff et al. (34) found that encapsulated P. gingivalis caused serious forms of infection. This observation was confirmed by Laine et al. (21), who demonstrated that mice challenged with encapsulated P. gingivalis developed more severe infections than those challenged with unencapsulated strains. Compositional analysis of the LPS and CPS of several P. gingivalis strains has revealed the complexity of these antigens. Bramanti et al. (3) reported that the polysaccharide component of P. gingivalis LPS consists of rhamnose, glucose, galactose, mannose, glucosamine, and galactosamine. Schifferle et al. (30) gingivalis LPS consists of the tetrasaccharide repeating unit -6)-␣-D-Glc p-(1-4)-␣-L-Rha p-(1-3)-␤-D-GalNAc-(1-3)-␣-D-Gal p-(1-.To date, 6 P. gingivalis capsule serotypes have been defined; however, serologic assessments of periodontitis patients suggest that additional P. gingivalis CPS-specific serotypes exist (4, 20, 32).Adult periodontal disease is one of the most common chronic infectious diseases of humans (24). Despite this, there are no vaccines in use for the prevention of adult periodontitis. Because P. gingivalis is a significant periodontal pathogen, investigators have assessed the potential of several P. gingivalis antigens to function as vaccine candidates, including killed whole P. gingivalis organisms and specific P. gingivalis antigens such as fimbriae, fimbrillin peptides, gingipains, hemagglutinins, and others (7,9,11,13,22,29,31). A conjugate vaccine consisting of P. gingivalis CPS and P. gingivalis fimbriae was shown to prevent P. gingivalis infection when a murine subcutaneous challenge model was used (6). However, the use of P. gingivalis CPS as a vaccine candidate has n...

show abstract

IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines

Cited by 67 publications

References 46 publications

Assignment of Weight-Based Immunoglobulin G1 (IgG1) and IgG2 Units in Antipneumococcal Reference Serum Lot 89-S(F) for Pneumococcal Polysaccharide Serotypes 1, 4, 5, 7F, 9V, and 18C

Assignment of Weight-Based Immunoglobulin G1 (IgG1) and IgG2 Units in Antipneumococcal Reference Serum Lot 89-S(F) for Pneumococcal Polysaccharide Serotypes 1, 4, 5, 7F, 9V, and 18C

IgG subclasses and avidity of antibodies to polysaccharide antigens in allogeneic BMT recipients after vaccination with pneumococcal polysaccharide and Haemophilus influenzae type b conjugate vaccines

Immunization withPorphyromonas gingivalisCapsular Polysaccharide PreventsP. gingivalis-Elicited Oral Bone Loss in a Murine Model

Contact Info

Product

Resources

About